Can a single antiplatelet drug beat aspirin after heart valve replacement?

NCT ID NCT05283356

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This trial compares two single antiplatelet therapies—ticagrelor versus aspirin—in people who have just undergone transcatheter aortic valve implantation (TAVI) for severe aortic stenosis. The goal is to see which drug better prevents serious complications like stroke, heart attack, and valve blood clots while keeping bleeding risks low. Participants must have additional conditions such as diabetes or coronary artery disease, which raise their risk of ischemic events.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ticagrelor
What this could lead to
If ticagrelor proves safer and more effective than aspirin, it could become the standard single antiplatelet therapy after TAVI, reducing strokes and heart attacks without raising bleeding risk.
What could go wrong
This is a phase 4 trial, but ticagrelor may still cause more bleeding than aspirin in some patients. Results may not apply to all TAVI recipients, especially those without the listed comorbidities.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AORTIC VALVE STENOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital Alvaro Cunqueiro

    RECRUITING

    Vigo, Pontevedra, 36312, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.